Atlas Brown Inc. Acquires 2,701 Shares of Pfizer Inc. (NYSE:PFE)

Atlas Brown Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,917 shares of the biopharmaceutical company’s stock after acquiring an additional 2,701 shares during the quarter. Atlas Brown Inc.’s holdings in Pfizer were worth $1,934,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Gladius Capital Management LP grew its holdings in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares during the period. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter valued at about $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer during the third quarter worth approximately $35,000. Joseph Group Capital Management increased its holdings in Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 771 shares in the last quarter. Finally, Strategic Financial Concepts LLC acquired a new position in Pfizer in the second quarter valued at approximately $38,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.4 %

Shares of NYSE:PFE traded down $0.11 on Friday, hitting $26.75. 24,283,658 shares of the company traded hands, compared to its average volume of 33,808,176. The company has a market cap of $151.59 billion, a PE ratio of 36.15, a PEG ratio of 0.63 and a beta of 0.64. The stock has a 50 day simple moving average of $26.21 and a 200-day simple moving average of $28.05. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the previous year, the company earned ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.43%. Pfizer’s dividend payout ratio (DPR) is presently 232.43%.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on PFE shares. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Citigroup assumed coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target for the company. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.